Raji CDX Model

The Raji cell line is derived from human Burkitt’s lymphoma, a highly aggressive B-cell non-Hodgkin lymphoma known for its association with the Epstein-Barr virus (EBV). Burkitt’s lymphoma is characterized by its translocation involving the MYC gene and its rapid tumor growth. The Raji cell line provides a quintessential platform for understanding the intricate biology, progression, and therapeutic challenges associated with Burkitt’s lymphoma. Representing key molecular features and genetic alterations, including the EBV positivity and MYC translocation, Raji holds significant relevance in preclinical lymphoma studies. The in vitro and in vivo behavior of Raji offers insights into the aggressive growth kinetics, metabolic activity, and therapeutic responsiveness of Burkitt’s tumors. Researchers utilize the Raji model extensively to dissect the molecular underpinnings of Burkitt’s lymphoma, evaluate novel therapeutic agents, and understand potential resistance mechanisms to current treatments.

Model Details

Cancer Location: Lymphoid
Cancer Type: Burkitt’s Lymphoma
Model Name: Raji
Mouse Strain: SCID-Beige, NSG
Treatment Data Available: Chemotherapy (Rituximab)

Raji Growth Curves

Raji CDX Model

Growth of subcutaneous Raji in SCID-Beige mice (n=5 mice).

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.